The Medicines Co. Joins Crowded Antibiotic Field With Q4 Orbactiv Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is banking on its single-dose treatment course to propel it over competitors in a crowded generic and branded space, but this may involve major changes in treatment practice, analysts say.